Pulmonary Langerhans Cell Histiocytosis
A Partnership with LAM
The Histiocytosis Association is excited to announce a newly formed partnership with the LAM Foundation whose mission is “To seek safe and effective treatments, and ultimately a cure, for lymphangioleiomyomatosis (LAM).” Because adult pulmonary Langerhans cell histiocytosis (PLCH) is often confused with LAM, physicians at the 26 LAM clinics have taken an interest in PLCH.
Relatively few studies have explored the natural history of PLCH, and the care of patients is often fragmented between hematology and oncology experts, pulmonologists, and other medical specialists with expertise in histiocytic disorders. For patients afflicted with this disease, the identification of appropriate care providers can be a very frustrating journey, as relatively few specialists have expertise in the management of histiocytic lung disorders like PLCH.
The Histiocytosis Association has partnered with the LAM Foundation to establish pulmonary Langerhans cell clinics within the LAM clinical settings to address the issues outlined above. Potentially, these clinics will assist PLCH patients with access to relevant experts in histiocytic lung diseases and promote increased awareness from the medical community. It is also hoped that such a network will facilitate future studies, increase knowledge, and improve future care for patients with PLCH.
Patients taking advantage of the pulmonary Langerhans cell histiocytosis/LAM clinics will alternate with their local pulmonary doctors and with the PLCH clinics.
Learn where the 26 PLCH clinics are located
and make arrangements to be seen by a participating physician.
Questions concerning this process should be directed to email@example.com